Skip to main content

Table 1 Overview of patients and healthy controls

From: Do fragments and glycosylated isoforms of alpha-1-antitrypsin in CSF mirror spinal pathophysiological mechanisms in chronic peripheral neuropathic pain? An exploratory, discovery phase study

Variables Patients
(n = 11)
Healthy controls
(n = 11)
Statistics
p-value
Age (years) 58 (35–75) 23 (20–28) < 0.001*
Sex (% female) 55% 55% 1.0
Body Mass Index (kg/m2) 24.7 (20.2–30.0) 22.6 (20.8–26.5) 0.065
Pain duration (months) 65 (30–180) 0 < 0.001*
Pain intensity (0–100 mm)a 72 (40–87) 0 < 0.001*
Opioid doseb (mg/day) 0 (0–480) 0 0.076
On opioids (%) 45% 0% 0.035*
On tricyclics or duloxetine (%) 36% 0% 0.090
On gabapentinoids (%) 36% 0% 0.090
On paracetamolc (%) 45% 0% 0.035*
On NSAIDc (%) 18% 0% 0.476
  1. Data are presented as median (range) or percentages. Furthest to the right is the result of the statistical comparisons between patients and healthy controls. * denotes significant group difference
  2. Notes:
  3. a: At inclusion, patients were asked to grade their average pain intensity for last week on a Visual Analogue Scale 0–100 mm, whereas the pain status of healthy controls was investigated by an extensive structured interview. All controls were free of pain
  4. b: In oral morphine equivalents
  5. c: Excluding treatment “as needed”. NSAID: Non-Steroidal Anti-Inflammatory Drug